Latest Patents

Patents imply intellectual property and it has a $ value that can be associated depending on the field and type of patent that is allocated. Patents also increase the enterprise value of the company and help prevent copy-cats from copying the idea without having royalt payments or licencing deals. We like it when companies get patents awarded!. To protect IP companies aggressively file provisional patents even before they have a working product. The below table provides a way to look at what has been done by companies and use this as a factor to make investment decisions.

     
Title Filing Date Publication Date Grant Date
Process for purifying fusion proteins 2023-3-24 2023-9-28
Novel il-18 variants 2022-12-22 2023-6-29
Novel fusion protein specific for ox40 and pd-l1 2022-11-18 2023-5-25
Proteins specific for cd137 2022-9-26 2022-11-30
Muteins of human lipocalin 2 (lcn2,hngal) with affinity for given target 2022-7-01 2022-10-19
Methods for preventing or treating certain disorders by inhibiting binding of … 2022-6-14 2023-1-19
Engineered t cells and uses therefor 2022-5-24 2022-9-22
Lipocalin muteins with binding affinity for ox40 2022-5-18 2022-11-24
Novel lipocalin muteins specific for connective tissue growth factor (ctgf) 2022-4-08 2022-10-13
Novel lipocalin muteins specific for connective tissue growth factor (ctgf) 2022-4-08 2022-10-13
Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine … 2022-3-24 2022-9-29
Her2/4-1bb bispecific fusion proteins for the treatment of cancer 2022-3-23 2022-9-29
Her2/4-1bb bispecific fusion proteins for the treatment of cancer 2022-3-23 2022-9-29
Lipocalin muteins with binding affinity for lag-3 2021-10-12 2022-3-31
Lipocalin muteins with binding affinity for LAG-3 2021-10-12 2023-10-03 2023-10-03
Biomarker methods and uses 2021-9-17 2022-3-24
Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3) 2021-8-04 2021-12-09
Novel fusion proteins specific for cd137 and gpc3 2021-7-07 2021-8-31
Multimeric immunomodulators targeting 4-1BB 2021-6-04 2023-6-09
Anti-cancer fusion polypeptide 2021-2-05 2021-12-30
New fusion proteins specific for cd137 and pd-l1 2021-1-26 2021-8-13
Tear lipocalin muteins binding il-4 r alpha 2020-12-16 2021-7-01
Anti-cancer fusion polypeptide 2020-11-12 2021-7-01
Her2/4-1bb bispecific fusion proteins for the treatment of cancer 2020-11-04 2021-5-14
Novel specific-binding polypeptides and uses thereof 2020-8-20 2021-3-04
Inhaled administration of lipocalin muteins 2020-3-27 2020-10-08
Lipocalin mutein for treatment of asthma 2020-3-25 2022-6-23
FUSION PROTEINS, NUCLEIC ACID MOLECULE, PRODUCTION METHODS, TO SIMULTANEOUSLY … 2020-2-25 2021-10-19
Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides … 2019-11-21 2020-5-14
Novel proteins specific for angiogenesis 2019-11-13 2020-5-07
Novel proteins specific for lag-3 2019-10-30 2020-2-13
Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis … 2019-8-27 2020-3-05
NEW FUSION PROTEIN SPECIFIC TO CD137 AND PD-L1 2019-7-31 2022-1-26
Novel fusion protein specific for cd137 and pd-l1 2019-7-31 2023-6-29
Humanized anti-pd-1 antibodies and uses thereof 2019-7-26 2020-1-30
Proteins specific for calcitonin gene-related peptide 2019-7-08 2021-6-15 2021-6-15
Fusion molecules 2019-4-24 2021-3-16 2021-3-16
Novel fusion polypeptide specific for lag-3 and pd-1 2018-10-23 2019-7-19
Novel proteins specific for pyoverdine and pyochelin 2018-8-14 2018-12-27
Muteins of tear lipocalin and methods for obtaining the same 2018-7-10 2019-1-17
Methods for preventing or treating disorders by increasing bioavailability of … 2018-3-28 2018-11-01
Novel fusion polypeptides specific for lag-3 and pd-1 2018-1-18 2018-7-26
Proteins specific for cd137 2017-11-08 2018-5-17
Methods for preventing, treating or diagnosing disorders 2017-10-20 2018-5-17
Human neutrophil gelatinase-associated lipocalin (hngal) muteins that bind … 2017-7-07 2017-12-28
Novel binding proteins for pcsk9 2017-2-28 2017-6-22
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of … 2016-11-02 2017-3-09
Anti-cancer fusion polypeptide 2016-5-18 2023-2-17
Muteins with tear lipocalin having affinity to human c-met receptor tyrosine … 2015-12-14 2016-7-14
Recombinant bacterial lipocalin blc and uses thereof 2015-2-12 2015-7-09
Multi-specific polypeptide useful for localized tumor immunomodulation 2015-1-12 2019-9-19 2019-9-19
Novel lipocalin-mutein assays for measuring hepcidin concentration 2014-2-05 2015-7-02
Controlled release formulation of lipocalin mutein 2012-8-08 2015-9-09 2015-9-09
MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4 2011-12-02 2017-10-23 2017-10-23
Muteins of human lipocalin 2 with affinity for Glypican-3 (GPC3) 2011-11-15 2013-5-23
Muteins of tear lipocalin and methods for obtaining the same 2011-6-23 2011-7-14
Muteins of human tear lipocalin 2009-8-19 2011-2-22 2011-2-22
Muteins of tear lipocalin and methods for obtaining the same 2007-8-01 2009-8-26
Muteins of apolipoprotein D 2006-9-25 2007-1-25
Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA- … 2005-11-25 2015-7-29
Muteins of a bilin-binding protein with affinity for a given target 2003-8-25 2010-4-06 2010-4-06
Soluble truncated polypeptides of the nogo-a protein 2002-10-31 2006-12-21
Muteins of human neutrophil gelatinase-associated lipocalin and related … 2002-9-18 2007-7-11 2007-7-11
Muteins of human neutrophil gelatinase-associated lipocalin and related … 2002-9-18 2003-6-26
Nouvelles muteines de lipocaline specifiques au facteur de croissance des … 2022-4-08 2022-10-13
Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar … 2020-2-25 2021-10-19